ReviewClinical nuclear medicine2013
Targeted α-particle therapy of bone metastases in prostate cancer.
Review in Clinical nuclear medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective.AAPS PharmSciTech · 2026Review
- Alpha Particle Emitter Radiolabeled Antibodies in Cancer Therapy: Current Status, Challenges, and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.International journal of molecular sciences · 2024Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma.Journal of bone oncology · 2021Review
- The Effect of Radium-223 Therapy in Agent Orange-Related Prostate Carcinoma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020Article
- Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.Cancer biotherapy & radiopharmaceuticals · 2020Article
- Development of Targeted Alpha Particle Therapy for Solid Tumors.Molecules (Basel, Switzerland) · 2019Review
- The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.International journal of molecular sciences · 2019Review
- Fluorescent nuclear track detectors for alpha radiation microdosimetry.Radiation oncology (London, England) · 2018Article
- Dosimetry-Based Consideration on Remission and Relapse after Therapy withDiagnostics (Basel, Switzerland) · 2018Article
- A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.Pathology oncology research : POR · 2017Article
- Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.Journal of experimental & clinical cancer research : CR · 2017Review
- Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.AJR. American journal of roentgenology · 2017Review
- Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.European journal of nuclear medicine and molecular imaging · 2016Article
- A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?Pharmaceuticals (Basel, Switzerland) · 2015Review
- One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.Cancer biotherapy & radiopharmaceuticals · 2015Article
- Article
- Recent advances in bone-targeted therapies of metastatic prostate cancer.Cancer treatment reviews · 2014Review
- Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Medical oncology is moving toward personalized and precision treatments. This evolution is spearheaded by ongoing discoveries on the fundamental machinery that controls tumor and hosts microenvironment biological behavior. α-Particles with their high energy and short range had long been recognized as potentially useful in the treatment of cancer. More than a century after the discovery of radium by the Curies, 223Ra dichloride is now available in the expanding armamentarium of therapies for metastatic castration-resistant prostate cancer. This advance occurs in the context of several other novel therapeutics in advanced prostate cancer that include more effective androgen receptor pathway inhibition, better chemotherapy, and immunotherapy. We present a concise review on the therapeutic use of 223Ra dichloride in this clinically important setting including excerpts on the radium history, physical properties, the alpharadin in symptomatic prostate cancer clinical trial, and practical information on its use in the clinic. It is anticipated that, with the current emergence of 223Ra as a viable form of therapy, interest in and use of α-particle therapy in the management of cancer will grow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.